Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 08/31/21
Due: 08/31/22
Phase: N/A
Priority: Normal
Start: 11/30/09
End: 06/30/16
Due: 06/30/17
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. | NCT02746744 | Anders Svenningsson | user2@example.com | None | 2016-05-31 | 2021-08-31 | 2022-08-31 | - | - | 2025-07-14 |
| Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis | NCT01719159 | Anders Svenningsson | user2@example.com | None | 2009-11-30 | 2016-06-30 | 2017-06-30 | - | - | 2025-07-14 |